Request and Response Register

Freedom of Information Request Reference: 11868

Date Received: 31/08/2026

Summary:
Request in relation to data on Housing Adaptations Across All Tenure Types.

Date of Response: 16/09/2026
View Response: 11868.pdf

Freedom of Information Request Reference: 11867

Date Received: 28/08/2026

Summary:
Please could you provide the product name and supplier name for the following software systems currently used by the Board: • EPR - Electronic Patient Record • PAS - Patient Administration System • Integration Engine / Interface Engine • ePMA - Electronic Prescribing and Medicines Administration • MIS - Maternity Information System • LIMS - Laboratory Information Management System • RIS - Radiology Information System • PACS - Picture Archiving and Communication System • Emergency Department / Urgent Care System • Patient Portal • Data Warehouse / BI / Analytics Platform • IAM / SSO - Identity, Access Management and Single Sign-On • EDMS - Electronic Document Management System • AVT - Ambient Voice Technology • Virtual Ward / Remote Patient Monitoring Platform

Date of Response: 14/09/2026
View Response: 11867.pdf

Freedom of Information Request Reference: 11862

Date Received: 28/08/2026

Summary:
Question 1: For the Neurodevelopmental Adult NW team, please provide the total number of patients on the waiting list for an adult ADHD assessment for each year from 2023 to the present date (August 2026, or the latest available date). Please provide a separate figure for each calendar year (2023, 2024, 2025, and 2026 to date). Question 2: Please provide the current number of clinicians working within the North West Locality who are qualified to diagnose ADHD in adults.

Date of Response: 14/09/2026
View Response: 11862.pdf

Freedom of Information Request Reference: 11857

Date Received: 25/08/2026

Summary:
I am seeking recorded information about NHS services available to neurodivergent children and young people aged under 18 within your Health Board area. For this request, “neurodivergent” should be interpreted broadly and should include, but not be limited to, autism and ADHD. Please provide the following information as at the date of this request. 1. Neurodevelopmental services Please identify each NHS service or pathway provided or commissioned by the Health Board specifically for neurodivergent children and young people aged under 18. For each service/pathway, please provide, where recorded: • service/pathway name; • age range; • neurodevelopmental conditions or needs supported; • whether a formal diagnosis is required; • eligibility criteria; • referral route; • geographical restrictions; and • the responsible department or directorate. 2. CAMHS and neurodivergence Please identify any CAMHS team, pathway or provision specifically intended or adapted for neurodivergent children and young people. For each, please state whether the Board records the availability of staff with a specific specialist role, qualification or remit relating to autism, ADHD or neurodivergence. I am not requesting staff names or personal information. 3. Sexual abuse, sexual assault and significant trauma Please identify any service provided or commissioned by the Board which supports children and young people aged under 18 who have experienced: • sexual abuse; • sexual assault or sexual violence; • peer-on-peer sexual abuse; or • significant psychological trauma. For each service, please provide: • service/provider name; • age range; • eligibility criteria; • referral route; • geographical restrictions; • whether the service is NHS-operated or externally commissioned; and • where externally commissioned, the provider and current contract/funding period. 4. Neurodivergent children who have experienced sexual abuse or trauma Please identify any service, pathway, protocol or commissioning arrangement specifically addressing the needs of neurodivergent children or young people who have experienced sexual abuse, sexual violence or significant trauma. Please state whether the Board has any specifically commissioned or designated clinical expertise addressing the combination of neurodivergence and psychological/sexual trauma. 5. Children unable or not ready to give a detailed verbal account For services identified under questions 3 or 4, please provide any recorded: • policy; • clinical guidance; • referral criteria; • service specification; • pathway document; or • commissioning requirement which addresses children or young people who, because of neurodivergence, communication differences, developmental needs or trauma, are unable or not yet ready to provide a detailed verbal account of what has happened to them. In particular, please state whether such a child can access assessment, relationship-building, stabilisation or therapeutic support without first being required to provide a detailed verbal disclosure or narrative of the traumatic event. If no recorded policy or provision addressing this is held, please state that. 6. Alternative and adapted communication Please identify any recorded provision within the services covered by questions 3–5 for: • non-verbal or reduced-verbal communication; • written or text-based communication; • visual communication; • augmentative or alternative communication; • sensory/environmental adaptations; • additional processing time; • predictable or structured therapeutic environments; or • other reasonable adaptations for neurodivergent children. 7. Referral outcomes Where centrally recorded and capable of being provided without reviewing individual patient records, please provide for the most recent 12-month period available: • number of under-18 referrals to the services identified under questions 3 and 4; • number accepted; • number declined or redirected; and • any centrally recorded categories/reasons for declined or redirected referrals. If the Board records “unable to engage”, “not ready”, “unable to disclose”, communication difficulties or similar reasons, please provide those categories and the corresponding aggregate numbers. I am not requesting patient-level information. 8. Waiting lists For each service identified under questions 1, 3 and 4, please provide the most recent centrally recorded: • number of children/young people waiting; and • average or median waiting time, where held. 9. Commissioned third-sector provision Please identify any charity, third-sector organisation or external provider currently funded or commissioned by the Health Board to provide: • neurodevelopmental support to children; • child sexual-abuse/sexual-violence support; • child trauma support; or • services addressing both neurodivergence and trauma. For each, please provide the service/provider, purpose of the commission, age range, current annual contract or funding value where recorded, and contract/funding period. 10. Policies, service specifications and rights assessments Please provide copies of, or links to, any current: • neurodevelopmental strategy or pathway; • child trauma/sexual-abuse pathway; • relevant service specification; • equality impact assessment; • children's rights or UNCRC assessment; or • needs assessment which addresses any of the services covered by this request. Where any document specifically considers neurodivergent children who have experienced abuse or trauma, please identify it.

Date of Response: 14/09/2026
View Response: 11857.pdf

Freedom of Information Request Reference: 11854

Date Received: 24/08/2026

Summary:
1. Please supply the name, job title, telephone number and email address of the commissioner with responsibility for mental health placements for adults aged 18 to 64, covering residential, nursing and supported living. 2. Please provide the total number of adults aged 18 to 64 with a primary diagnosis of mental health funded by the Health Board in long-term care – residential care, nursing care and supported living separately. Please give an end-of-year snapshot (at 31 March) for each of 2022/23, 2023/24, 2024/25 and 2025/26, and the most up-to-date figure available for 2026/27. 3. Please provide the number of new long-term placements made for adults aged 18 to 64 with a mental health need – residential care, nursing care and supported living separately. Please give the number during 2025/26 (year to 31 March 2026) and during 2026/27 to date. 4. Please provide the highest, lowest and average weekly rate paid for placements for adults aged 18 to 64 with a mental health need – residential care, nursing care and supported living separately – for 2026/27 or the latest year available, together with the average for 2025/26 for comparison. For supported living, please give the care and support fee only, excluding rent and housing costs, and please state the average hourly rate if care and support is commissioned by the hour. If you use weekly rate bands, please give these too. 5. Please provide a list of providers of residential care, nursing care and supported living used by the Health Board for adults aged 18 to 64 with a mental health need. For each provider, please give the setting (residential, nursing or supported living), the number of service users, and the gross expenditure, using the latest month available (or financial year 2025/26 if not), and state the month used.

Date of Response: 11/09/2026
View Response: 11854.pdf

Freedom of Information Request Reference: 11852

Date Received: 21/08/2026

Summary:
For each site the Board operates, please provide: 1. Designated disabled parking bays — the number, and the location of each: which car park, and grid reference, latitude/longitude or postcode if held. 2. Accessible toilets — the location of wheelchair-accessible toilets, by building, floor and department, and whether each needs a RADAR key. 3. Changing Places toilets — whether the Board has a facility meeting BS 8300, where it is, and its opening arrangements. 4. Step-free entrances and accessible drop-off — which entrances are step-free, and where any designated accessible drop-off point is.

Date of Response: 11/09/2026
View Response: 11852.pdf

Freedom of Information Request Reference: 11851

Date Received: 13/08/2026

Summary:
I would be grateful if you could provide: 1. An explanation of the PSB process and its intended purpose. 2. Details of the response timescales currently applied to patients receiving appointment booking correspondence. 3. The rationale and evidence supporting those timescales. 4. An explanation of the specific operational problem or objective that this process is intended to address, and how NHS Lothian measures whether it is achieving that objective. 5. Details of any equality, accessibility or patient experience considerations that informed the design of the process. 6. An explanation of why appointments staff are unable to exercise discretion where a patient makes contact shortly after a deadline has expired. 7. Information on how NHS Lothian monitors the impact of this process on patient access and patient experience. 8. Confirmation of whether NHS Lothian has reviewed the effectiveness of this process and, if so, the outcome of any such review. I would also be interested to understand: • How many working days patients are actually given to respond before being removed from the booking pathway. • Whether any audit has been undertaken regarding the number of patients who fail to respond within the timescale. • Whether NHS Lothian has assessed whether the process disproportionately affects particular patient groups.

Date of Response: 10/09/2026
View Response: 11851.pdf

Freedom of Information Request Reference: 11849

Date Received: 20/08/2026

Summary:
• Spend on Insourcing from May 2026-end of July 2026, broken down by each specialty and subspecialty, and the insourcing company that was used, e.g. cardiology £1000- echo cardiogram £1000- company x £1000 • The budget for each specialty for insourcing • Confirm the contract start and end date for each specialty • What frameworks were used for each specialty and was there direct awards and if so, who was they awarded to and what specialty • What was the service, e.g. theatres, outpatient, or diagnostic

Date of Response: 10/09/2026
View Response: 11849.pdf

Freedom of Information Request Reference: 11848

Date Received: 20/08/2026

Summary:
I am making a request under the Freedom of Information (Scotland) Act 2002 concerning the Scottish Specialist Prosthetics Service (SSPS) and the provision of specialist prosthetic foot and ankle technology. Published information concerning the Scottish Specialist Prosthetics Service refers to specialist foot and ankle joints and self-aligning ankle-feet. I would therefore be grateful for the following existing recorded information. 1. Current eligibility and prescribing criteria Please provide the current SSPS clinical eligibility and prescription criteria for: • specialist foot and ankle joints; • self-aligning ankle-feet; • hydraulic ankle-foot systems; • microprocessor-controlled ankle-foot systems; • powered or electronically controlled ankle-foot systems. 2. Devices available through SSPS Please provide the current list, formulary, prescribing matrix or schedule of ankle-foot devices which may be funded or supplied through SSPS. In particular, please provide the recorded status of: • Blatchford Elan / ElanIC; • Blatchford Echelon; • Blatchford Echelon VT; • Ottobock Meridium; • Ottobock Empower; • Össur Proprio Foot; • any other microprocessor-controlled, powered, electronically controlled or self-adjusting ankle-foot system. Please indicate, where recorded, whether each is: • routinely available; • available subject to clinical criteria; • restricted; • exceptional funding only; • available for clinical trial; • or not available. 3. Devices actually provided For each of the following financial years, please provide the number of devices approved, funded or supplied through SSPS, broken down by model where this information is held: • 2023/24; • 2024/25; • 2025/26; • 2026/27 to the date of this request. In particular, please provide figures for: • Elan / ElanIC; • Meridium; • Empower; • Proprio Foot; • Echelon / Echelon VT; • other advanced electronic or microprocessor ankle-foot systems. No patient-identifiable information is requested. 4. Applications and outcomes Please provide the number of applications or referrals for specialist ankle-foot technology during the above periods which were: • approved; • declined; • deferred for further assessment; • approved following a clinical trial. 5. Clinical criteria Please provide any written criteria used when considering a patient for specialist ankle-foot technology, including any recorded consideration of: • bilateral lower-limb amputation; • falls risk; • slopes, stairs and uneven terrain; • restricted knee function or other joint impairment; • pain or abnormal joint loading; • energy expenditure; • community mobility; • employment or occupational requirements; • rehabilitation potential. 6. Component trials Please provide any current policy concerning clinical trials of advanced prosthetic ankle-foot components, including: • manufacturer demonstration devices; • loan components; • comparative component trials; • trials prior to a final funding decision. 7. Financial criteria Please provide any: • financial threshold; • price ceiling; • additional approval procedure; • exceptional funding mechanism applicable to specialist ankle-foot prescriptions. 8. Reviews of advanced ankle technology Please provide copies of any product evaluations, technology reviews, committee papers, formulary reviews or policy reviews produced since 1 April 2023 concerning: • Elan / ElanIC; • Meridium; • Empower; • Proprio Foot; • microprocessor ankle-foot systems generally; • powered ankle-foot systems; • self-aligning ankle-feet. 9. Referral and cross-border access Please provide the current referral pathway to the Scottish Specialist Prosthetics Service, including: • which clinicians may refer; • whether referral must originate from a Scottish prosthetic centre; • residency requirements; • whether cross-border NHS referrals from England, Wales or Northern Ireland can be accepted; • whether a patient ordinarily resident in England can be assessed or treated by SSPS where their English NHS commissioner agrees to fund the assessment or treatment. 10. Which organisation holds the information? Where different elements of this request are held separately by: • NHS National Services Scotland; • WestMARC / NHS Greater Glasgow and Clyde; • SMART / NHS Lothian,

Date of Response: 11/09/2026
View Response: 11848.pdf

Freedom of Information Request Reference: 11846

Date Received: 20/08/2026

Summary:
I note that the West Lothian Chief Nurse Matched Job Report states, under factor 2. Knowledge, Training and Experience, that the applicant should have "advanced theoretical and practical knowledge, professional knowledge acquired through degree /diploma supplemented by specialist training, experience, short courses to doctorate level or equivalent". (See attached Matched Job Description). Doctorate level is SCQF Level 12. How does the post holder evidence that they have KTE to doctorate level/SCQF Level 12. Which SCQF Level 12 courses would evidence KTE at Level 8. SCPHN Specialist School Nurses can easily demonstrate that they have a Masters Level/SCQF Level 11 qualification (it's on the certificate) yet it's not clear how NHS Lothian Chief Nurses prove that they have knowledge, training and skills at PhD level/ SCQF Level 12. Please explain this inconsistency to me and tell me which SCQF Level 12 short courses are required for the post.

Date of Response: 11/09/2026
View Response: 11846.pdf

Freedom of Information Request Reference: 11845

Date Received: 20/08/2026

Summary:
Under freedom of information please can you provide all materials your health board has provided to staff which refers to first cousin marriage. This should include any guidelines or advice provided to NHS staff in your board area regarding first cousin marriage and any health implications for future children. This should also include any training materials provided to NHS staff in your health board area which covers the subject of first cousin marriage and any health implications for future children.

Date of Response: 11/09/2026
View Response: 11845.pdf

Freedom of Information Request Reference: 11843

Date Received: 19/08/2026

Summary:
I wish to appeal response 11629. You claim you cannot provide me with information because corridor care is not practised at St Johns Hospital. I did not ask if it is practised, I asked if it has occurred and that’s a very different thing. No hospital wants it to happen and no hospital would claim it’s practised but I believe across the country many doctors and nurses have acknowledged that due to sheer necessity patients have at some points been cared for in unconventional and sometimes inappropriate settings. I find it hard to believe that have never been any concerns raised about a single instance of this happening. I would like to request that you look again and check in each leader of staff’s inbox to make sure that corridor care of any kind hasn’t ben raised.

Date of Response: 16/09/2026
View Response: 11843.pdf

Freedom of Information Request Reference: 11842

Date Received: 19/08/2026

Summary:
I wish to appeal FOI response 11694. Every other health board has happily provided what I asked for. If you insist that what I have asked for makes a person 'identifiable' then please explain in detail why that is the case. I don't understand how revealing that an individual waited for example 66 weeks to start treatment identifies them in anyway? Who could possibly know that information about someone other than the person themself and some of their family members? I would suggest you reconsider your reason for not fulfilling my request. No other board agrees with your rationale and clearly have no fears about data making patients identifiable. As I have already said, if you believe it can identify someone then explain to me in detail why that's the case - don't just assert it.

Date of Response: 16/09/2026
View Response: 11842.pdf

Freedom of Information Request Reference: 11841

Date Received: 19/08/2026

Summary:
Request in relation to CCTV footage.

Date of Response: 07/09/2026
View Response: 11841.pdf

Freedom of Information Request Reference: 11840

Date Received: 19/08/2026

Summary:
Can you please tell me how many consultant doctors work full time and how many doctors work part time in each department I e cardiology,,vascular , orthopaedics and so on?

Date of Response: 11/09/2026
View Response: 11840.pdf

Freedom of Information Request Reference: 11839

Date Received: 19/08/2026

Summary:
For each financial year from 2019/20 to 2026/27 (most recent): 1. the total number of referrals for a Vasectomy 2. the median completed wait (in days) for a Vasectomy 3. the longest completed waited (in days) for a Vasectomy 4. the median ongoing wait (in days) for a Vasectomy 5. the longest ongoing wait (in days) for a Vasectomy

Date of Response: 10/09/2026
View Response: 11839.pdf

Freedom of Information Request Reference: 11836

Date Received: 17/08/2026

Summary:
Please provide recorded data regarding patient attendances and recorded presentations across your Health Board area over the past 10 calendar years (from 1 January 2016 to 31 December 2025, plus the available year-to-date figures for 2026). 1. Scope of Data Requested Please provide the annual counts/incidences (broken down by calendar year, individual hospital site/A&E department, and, where recorded, local GP practice cluster/postcode sector) for patient attendances/presentations associated with each of the following conditions: 1. Migraines (including ICD-10 G43 or relevant presenting complaint / Read / SNOMED codes) 2. Headaches (including ICD-10 R51 or equivalent) 3. Nausea and vomiting (including ICD-10 R11 or equivalent) 4. Balance problems / Vertigo / Dizziness (including ICD-10 R42, H81 or equivalent) 5. Depression (including ICD-10 F32, F33 or equivalent) 6. Sleep deprivation / Insomnia / Sleep disorders (including ICD-10 G47, F51 or equivalent) 7. Skin conditions (including ICD-10 L00–L99 or equivalent) 8. Cardiac conditions (including ICD-10 I00–I52, I20–I25 or equivalent) 9. Respiratory conditions (including ICD-10 J00–J99, J45 or equivalent) 10. Mental health presentations / referrals 11. Referrals to secondary physical or psychological healthcare services arising from the above presentations.

Date of Response: 10/09/2026
View Response: 11836.pdf

Freedom of Information Request Reference: 11835

Date Received: 17/08/2026

Summary:
Please provide the following information, as of 1 August 2026 (or most recent) 1) How many staff are currently employed on a full-time basis in GP walk-in clinics, broken down by (a) GP, (b) nurse and (c) administration and other staff. 2) By headcount, how many staff are currently employed in GP walk-in clinics, broken down by (a) GP, (b) nurse and (c) administration and other staff. 3) By FTE (full time equivalent), how many staff are currently employed in GP walk-in clinics, broken down by (a) GP, (b) nurse and (c) administration and other staff.

Date of Response: 11/09/2026
View Response: 11835.pdf

Freedom of Information Request Reference: 11834

Date Received: 17/08/2026

Summary:
Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which. Q2. Of the multiple myeloma patients over the past 6 months, how many were treated with the following: • Belantamab Mafodotin [Blenrep] • Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone • Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone • Bortezomib [Velcade] • Bortezomib [Velcade] + Dexamethasone • Bortezomib [Velcade] + Melphalan + Prednisolone/Dexamethasone (VMp or VCd) • Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) • Carfilzomib [Kyprolis] + Dexamethasone • Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) • Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) • Daratumumab [Darzalex] monotherapy • Elranatamab • Idecabtagene vicleucel [Abecma] • Isatuximab [Sarclisa] subcutaneous injection + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) • Isatuximab [Sarclisa] + Pomalidomide [Imnovid] + Dexamethasone (IsaPd) • Ixazomib [Ninlaro] + Lenalidomide [Revlimid] + Dexamethasone (IRd) • Lenalidomide [Revlimid] + Dexamethasone • Lenalidomide [Revlimid] monotherapy • Panobinostat + Bortezomib + Dexamethasone • Pomalidomide [Imnovid] + Dexamethasone • Selinexor + Bortezomib [Velcade] + Dexamethasone • Selinexor + Dexamethasone • Talquetamab • Teclistamab [Tecvayli] • Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify] Q3. In the last 6 months, how many patients have been initiated* on the following regimens? • Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone • Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone • Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) • Carfilzomib [Kyprolis] + Dexamethasone • Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) • Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) • Isatuximab [Sarclisa] subcutaneous injection + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) • Lenalidomide [Revlimid] monotherapy • Lenalidomide [Revlimid] + Dexamethasone • Selinexor + Bortezomib [Velcade] + Dexamethasone • Selinexor + Dexamethasone • Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify] *Patients are considered initiated if they have not received any of the drugs in the named regimen (either alone or in combination) in the 6 months prior to initiation. Q4. In the last 6 months, how many patients have received the following second-line treatment? • Lenalidomide [Revlimid] + Dexamethasone Q5. Does your trust participate in any clinical trials for multiple myeloma? If so, please provide the name of each trial, and the number of patients taking part.

Date of Response: 10/09/2026
View Response: 11834.pdf

Freedom of Information Request Reference: 11831

Date Received: 17/08/2026

Summary:
1. How many referrals have been made to CAMHS from GP for primary school aged children in each of the years 2022/23/24/25 & 26 so far? 2. Of these referrals, how many were not accepted by CAMHS and referred back to primary care (GP)? 3. How many referrals to CAMHS were made from GP for secondary school aged children in the years 2022/23/24/25 and 26 so far? 4. Of these referrals, how many were not accepted by CAMHS and referred back to primary care? 5. Of the referrals that were accepted, what was the average number of appointments with were attended prior to being discharged?

Date of Response: 10/09/2026
View Response: 11831.pdf

Freedom of Information Request Reference: 11829

Date Received: 14/08/2026

Summary:
Request in relation to research studies.

Date of Response: 11/09/2026
View Response: 11829.pdf

Freedom of Information Request Reference: 11828

Date Received: 14/08/2026

Summary:
Please could you provide the information broken down by individual hospital site (where applicable), rather than as a single trust-wide total. Where your organisation operates more than one hospital, we would be grateful for a separate entry for each site. For each hospital site, we are specifically looking for the following: • Hospital name: • Number of cardiographs on site: • Make and model of each cardiograph: • Commission date (year): • Planned replacement date (year): • Do you operate a paper-based or digital ECG workflow? • Do you have an ECG management system? (If yes, please state the make/model)

Date of Response: 11/09/2026
View Response: 11828.pdf

Freedom of Information Request Reference: 11827

Date Received: 13/08/2026

Summary:
• Does this health board have a service – such as a weight management service - that is currently allowing/prescribing access to GLP-1s for the weight loss indication? • If so, what are the criteria for access to GLP-1s for the weight loss indication? • If your health board has this service, please tell me the number of people currently on the waiting list to access this service? • How many people were on the waiting list at the same time in previous years, broken down by year, dating back to 2016? • What capacity does the service have for appointments per year? • How long is the average wait for a person to see a specialist? • How long is the longest wait a person has faced to see a specialist? • If someone is placed on the waiting list now, how long would they wait? • If your health board prescribes GLP-1s for the weight loss indication, how many patients have been prescribed this medication for weight loss, either as the primary reason or a comorbidity? • How many patients have been prescribed GLP-1s for weight loss, broken down by month, in the last year?

Date of Response: 04/09/2026
View Response: 11827.pdf

Freedom of Information Request Reference: 11826

Date Received: 13/08/2026

Summary:
1. Please confirm whether any hospitals in your area have reported leaks which have resulted in sewage coming into the hospital (through ceilings, walls etc) 2. If the answer to question 1 is yes, please provide a breakdown of a)which hospitals and b) how many times they have reported this happening since 2021

Date of Response: 04/09/2026
View Response: 11826.pdf

Freedom of Information Request Reference: 11825

Date Received: 13/08/2026

Summary:
Please use 1 November 2025 as the relevant starting date where an item asks which version was in force. 1. The Workforce/Employee Relations Scheme of Delegation, delegated-authority matrix or equivalent framework in force from 1 November 2025 to the present governing: a. the appointment of Stage 1 and Stage 2 grievance Chairs or panels; b. the required organisational seniority or management level of those Chairs; c. the authority to make findings and determine grievance outcomes; d. the authority to require or implement actions arising from an outcome; and e. any distinction between authority to determine an outcome and authority merely to make recommendations. 2. Any NHS Lothian procedure, guidance, checklist, standard operating procedure, template or decision tool used to assess a proposed grievance Chair’s: a. prior involvement; b. impartiality; c. organisational seniority; d. delegated authority; and e. authority to implement an outcome. 3. Any recorded guidance explaining: a. who may select or authorise a grievance Chair; b. whether that selection or authorisation must be recorded; c. where the record must be stored; and d. which department or role is responsible for maintaining it. 4. The applicable records-management or retention schedule for: a. grievance case files; b. Employee Relations case-management records; c. grievance Chair appointment and authorisation records; d. panel-composition and conflict-of-interest checks; and e. correspondence concerning reconsideration or replacement of a Chair. 5. Any recorded guidance describing when a grievance should be chaired by: a. a manager from another service or directorate; b. a Service Director; c. a person of greater seniority than originally proposed; or d. another appropriately senior equivalent manager because of the subject matter, complexity or seniority of individuals whose actions are under consideration. 6. Any current organisational chart or role-authority document sufficient to show the reporting and management levels of: a. Associate Medical Director; b. Associate Nurse Director; c. Deputy Associate Nurse Director; d. Diagnostics Manager; e. Clinical Director; and f. Service Director, insofar as relevant to the grievance Scheme of Delegation. 7. Any recorded information stating whether Employee Relations is expected to retain, or have access to, records evidencing the selection, authorisation, prior-involvement assessment and delegated authority of Chairs in ongoing grievance cases.

Date of Response: 04/09/2026
View Response: 11825.pdf

Freedom of Information Request Reference: 11824

Date Received: 13/08/2026

Summary:
I am aware that NHS Lothian has a policy on the above area, and I assume that it is being reviewed as a direct result of the Supreme Court ruling in April 2025 on the definition of ‘sex’ as a protected characteristic. Given the court’s decision was made over a year ago now, I am writing to ask NHS Lothian under the Freedom of Information (Scotland) Act 2002 to provide me with the following information. 1. Has NHS Lothian completed a review of the policy in light of the For Women Scotland Ltd v The Scottish Ministers case decision ? 2. If so, please provide me with a copy of the reviewed policy, as well as a copy of the original policy 3. If not, please provide a date by when the review will be completed 4. What was the definition of ‘trans people’ used by NHS Lothian prior to the Supreme Court decision and when was it first adopted ? 5. What was the legal basis for adopting such a definition – please state detailed citations of law(s) 6. What was the definition of ‘non-binary people, used by NHS Lothian prior to the Supreme Court decision and when was it first adopted ? 7. What was the legal basis for adopting such a definition – please state detailed citations of law(s) 8. What is the current definition of ‘trans people’ being used by NHS Lothian as a result of the review process and aimed to be compliant with the Supreme Court decision – please include detailed citations of law(s) supporting this definition 9. What is the current definition of ‘non-binary people’ being used by NHS Lothian as a result of the review process and aimed to be compliant with the Supreme Court decision – please include detailed citations of law(s) supporting this definition As part of the overall review process, what steps has NHS Lothian taken to ensure that the voices of staff and service users who hold ‘gender critical’ views have/have had a sustained and detailed involvement in the review process? Beyond the review process, what steps has NHS Lothian taken to ensure that the voices of staff and service users who hold ‘gender critical’ views are routinely involved in the development of policy and practice in future? Finally, has the review process also looked at the evolution of NHS Lothian policy on trans and non-binary people to identify where the flawed position adopted by NHS Lothian was initiated or triggered, and what changes are being introduced to avoid a repeat of adopting flawed policy?

Date of Response: 10/09/2026
View Response: 11824.pdf

Freedom of Information Request Reference: 11823

Date Received: 12/08/2026

Summary:
1. Of those patients who experienced delayed discharge and were discharged in (i) 2024/25, and (ii) 2025/26, how many were delayed due to health and social care reasons for (a) 1-3 months, (b) 3-6 months (c) 6-9 months, (d) 9-12 months, (e) 12-18 months, (f) 18-24 months, and (g) over 24 months? 2. What was the longest any patient discharged in (i) 2024/25, and (ii) 2025/26 was delayed due to a delayed discharge based on health and social care reasons? What proportion of this delay was attributed to each of (a) assessment, (b) funding, (c) place availability, (d) care arrangements and (e) transport? 3. Of those patients currently experiencing delayed discharge due to health and social care reasons, how many have been delayed for (a) 1-3 months, (b) 3-6 months (c) 6-9 months, (d) 9-12 months, (e) 12-18 months, (f) 18-24 months, and (g) over 24 months? 4. What is the longest any patient currently experiencing delayed discharge due to health and social care reasons has been delayed? What proportion of this delay is attributable to each of (a) assessment, (b) funding, (c) place availability, (d) care arrangements and (e) transport?

Date of Response: 04/09/2026
View Response: 11823.pdf

Freedom of Information Request Reference: 11822

Date Received: 12/08/2026

Summary:
I am writing to request the following information under the Freedom of Information Act 2000 Name and contact details for the following:- Director of Estates Associate Director of Estates Director of Capital Projects Associate Director of Capital Projects Director of Facilities Associate Director of Facilities Head of Estates Head of Facilities Head of Capital projects Person responsible for Fire Compliance Person Responsible for Asbestos compliance Person responsible for Medical Gas Compliance If possible, please also provide the senior leadership structure within Estates & Facilities (e.g. Director of Estates, Deputy Director, Associate Directors, Heads of Service).

Date of Response: 07/09/2026
View Response: 11822.pdf

Freedom of Information Request Reference: 11821

Date Received: 12/08/2026

Summary:
Q1. For each of the financial years FY22/23, FY23/24, FY24/25 and FY25/26 (or the most recent available), please state the Health Board's total expenditure on interpreting services, broken down by delivery mode, and state expenditure on written document translation separately. Face-to-face interpreting Telephone interpreting Video interpreting Interpreting subtotal Document translation Total Q2. For each of the same four financial years, please state the number of interpreting requests or bookings received, and the number that were fulfilled. Requests / bookings received Requests / bookings fulfilled Q3. Which provider(s) deliver the Health Board's interpreting services, and what was the annual expenditure with each provider for each of the four financial years? And for each current interpreting contract, please state the date the contract came into effect, its current end date, and whether there is an option to extend (and if so, until when). Q4. Through which procurement framework(s) or contract(s), if any, are these services commissioned (for example a national Scottish Government framework, a regional framework, or a local Health Board contract)? Q5. For the most recent financial year (FY25/26 or the latest available), what proportion of interpreting expenditure fell within each of the following care settings? Secondary care Primary care Other community settings Total Q6. Does the Health Board have any plans to further expand interpreting provision into additional care settings (for example primary care or community settings)? If so, please indicate which settings, and the projected expenditure by setting and by financial year.

Date of Response: 07/09/2026
View Response: 11821.pdf

Freedom of Information Request Reference: 11820

Date Received: 12/08/2026

Summary:
Please could you provide the following information in relation to your organisation: 1. Do you currently have a policy, standard operating procedure, framework, governance document or equivalent process that applies to the introduction, approval, oversight or monitoring of: o New interventional procedures; o Novel surgical procedures; o Innovative procedures; or o Procedures undertaken for the first time within your organisation? 2. If such a document exists, please provide: o The title of the current document; o A copy of the document (PDF or Word format preferred); o The date on which the current version became effective, active, approved or implemented; o The date of the most recent review; and o The next scheduled review date (if applicable). 3. If your organisation uses a process that is not contained within a standalone policy document, please provide: o A description of the governance process used; o Any associated approval forms, checklists, committee terms of reference or governance documentation used to assess and approve new procedures. 4. Please indicate whether your process specifically addresses any/all of the below: o New surgical procedures; o New interventional radiology procedures; o New endoscopy procedures; o New cardiology procedures; o Use of new devices or implants; and o Procedures undertaken as part of innovation, research, service development or service transformation. 5. During the period 1 January 2023 to 1 January 2026, please provide: o The total number of applications, proposals or approvals for new, novel or innovative interventional procedures considered through this process; o The number approved; o The number declined or not approved; o Where available, a breakdown by specialty (for example surgical speciality, interventional radiology, cardiology, endoscopy or other specialties). 6. Please indicate: o Which committee, group or executive lead is responsible for approving new procedures within your organisation (title only). 7. Please state whether your organisation maintains a register, database, tracking system or log of approved new or innovative procedures and, if so, please provide: o A copy of the register or log (with any necessary redactions for personal information); o The procedure name or title; o The specialty involved; o The date of approval; o The current status (for example approved, piloted, implemented, suspended or withdrawn), where recorded. 8. Please indicate whether any new interventional procedures, surgical innovations or first-in-organisation procedures have been approved through an expedited, emergency or exceptional approval route (EG Chairs action) since 1 January 2023 and, if so, provide: o The procedure name; o The approving body; and o The year of approval.

Date of Response: 11/09/2026
View Response: 11820.pdf

Freedom of Information Request Reference: 11819

Date Received: 12/08/2026

Summary:
Please provide the following information regarding the Chalmers Gender Identity Clinic and their surgical assessment waitlist: 1) How many patients have been added to the surgical assessment waiting list, for each month since October 2023 until now? (ie. 100 patients in October 2023, 150 in November 2023, etc.) 2) How many patients have had their first surgical assessment per month in 2026? 3) Have there have been any issues which have caused a significant decrease in how many first surgical assessments have been provided? 4) What plans are there to speed up the surgical assessment waitlist, if any?

Date of Response: 14/09/2026
View Response: 11819.pdf

Freedom of Information Request Reference: 11818

Date Received: 11/08/2026

Summary:
We are writing to formally request a review of the health board’s response to our request (Ref: 11532) for ADHD and ASD referral and waiting time data for: 1. Children and young people services 2. Adult services For each calendar year: • 2024 • 2025 (to date, if full-year data are not yet available) We are dissatisfied with the decision to withhold this information on the basis that the data is combined within your Neurodevelopmental Assessment service and separate data cannot be obtained without exceeding the cost limit. Please review this decision and provide the combined neurodevelopmental service referral and waiting time data for both adults and children for the requested periods as in the original request. If available, please also provide a list of the conditions which are part of your Neurodevelopmental Assessment service.

Date of Response: 08/09/2026
View Response: 11818.pdf

Freedom of Information Request Reference: 11817

Date Received: 10/08/2026

Summary:
Q1. How many patients has your Trust treated (for any medical condition) in the past 3 months with the following drugs: •Alprolix •BeneFIX •Haemate P •Idelvion •Refixia •Rixubis •Veyvondi •Voncento •Wilate •Willfact Q2. How many patients have been treated in the past 3 months with: •Marstacimab for Haemophilia B ONLY •Hemgenix •Desmopressin for Von Willebrand Disease ONLY •Tranexamic Acid for Von Willebrand Disease ONLY Q3. Of the patients that were treated with Veyvondi in the past 3 months, how many patients received treatment: •Prophylactically •During surgery •On demand to treat bleeding episodes Q4. Of the patients that were treated with Voncento in the past 3 months, how many patients received treatment: •Prophylactically •During surgery •On demand to treat bleeding episodes Q5. How many patients are registered with your trust for the following diseases: •Haemophilia B •Von Willebrand Disease •Von Willebrand Disease - paediatric patients (age 17 or under)

Date of Response: 02/09/2026
View Response: 11817.pdf

Freedom of Information Request Reference: 11816

Date Received: 10/08/2026

Summary:
I would like to request aggregate information about surgical procedures involving the temporomandibular joint undertaken by, or on behalf of this NHS board. For each financial year from 1996/97 to 2025/26 inclusive, please provide the number of procedures recorded in each of the following categories: 1. Primary total or partial prosthetic replacement of the temporomandibular joint. 2. Revision, replacement or removal of a temporomandibular-joint prosthesis or component. 3. Temporomandibular-joint arthroscopy, including arthroscopic lavage, lysis or adhesiolysis. 4. Temporomandibular-joint arthrocentesis or lavage. 5. Other open operations on the temporomandibular joint, including arthroplasty, reconstruction, meniscectomy or discectomy. Please provide the figures broken down by financial year and procedure category. Where this information is readily available from the same data system, please also distinguish between: • The number of operative episodes or procedures. • The number of individual patients.

Date of Response: 03/09/2026
View Response: 11816.pdf

Freedom of Information Request Reference: 11815

Date Received: 10/08/2026

Summary:
Please treat this request under the Freedom of Information (Scotland) Act 2002 and, insofar as any requested information constitutes environmental information, the Environmental Information (Scotland) Regulations 2004, as appropriate. NHS Lothian's Finance and Resources Committee paper “RIE Supplemental Agreement – Joint Lifecycle Management”, dated 10/06/2026, records that NHS Lothian formally concluded the Supplemental Agreement with Consort, funders and other related parties on 07/04/2026. The same paper records that the anticipated Available Sums were expected to fall well short of the funding required for Fire Safety Works and outstanding Lifecycle Works; that this expectation was notified to the Scottish Government; and that the Scottish Government's written response dated 15/04/2024 was provided to the NHS Lothian Board at its private session on 24/04/2024. Please provide: 1. The executed Supplemental Agreement concluded on 07/04/2026, including its schedules, annexes and appendices forming part of the executed agreement. 2. The Scottish Government written response dated 15/04/2024 referred to above.

Date of Response: 04/09/2026
View Response: 11815.pdf

Freedom of Information Request Reference: 11814

Date Received: 07/08/2026

Summary:
Could you please provide me with a list of the primary care rebates your ICB/ Health Board is currently signed up to? Could you please provide the start and end dates of the contracts.

Date of Response: 03/09/2026
View Response: 11814.pdf

Freedom of Information Request Reference: 11813

Date Received: 07/08/2026

Summary:
Q1. How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease. Q2. In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products? •Altuvoct •Advate •Adynovi •Elocta •Esperoct •Factor Eight Inhibitor Bypass Activity (FEIBA) •Hemlibra (standalone) •Hemlibra in combination with any Factor VIII •NovoEight •NovoSeven RT •Nuwiq •Obizur •Refacto AF •Any other products •Marstacimab •Cevenfacta Q3. For patients treated with Advate in the last three months, please provide: •The number of haemophilia A patients treated prophylactically •The number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds) Q4. In the last three months, how many patients were treated with the following products for severe Haemophila A ONLY? •Altuvoct •Advate •Adynovi •Elocta •Esperoct •Factor Eight Inhibitor Bypass Activity (FEIBA) •Hemlibra (standalone) •Hemlibra in combination with any Factor VIII •NovoEight •NovoSeven RT •Nuwiq •Obizur •Refacto AF •Any other products •Marstacimab •Cevenfacta

Date of Response: 02/09/2026
View Response: 11813.pdf

Freedom of Information Request Reference: 11812

Date Received: 06/08/2026

Summary:
Q1. Within your trust, how many patients currently have a diagnosis for: • Fabry(-Anderson) disease (ICD10 code E75.21) • Gaucher disease (ICD10 code E75.22) • Pompe disease (ICD10 Code E74.02) • Pompe disease (ICD10 Code E74.02) infantile onset (patients diagnosed before age 1) • Hunter syndrome (MPS II) (ICD10 code E76.1) Q2. Of the patients above, how many patients have been newly diagnosed within the past 3 months for: • Fabry(-Anderson) disease (ICD10 code E75.21) • Gaucher disease (ICD10 code E75.22) • Pompe disease (ICD10 Code E74.02) • Pompe disease (ICD10 Code E74.02) infantile onset (patients diagnosed before age 1) • Hunter syndrome (MPS II) (ICD10 code E76.1) Q3. How many patients have been treated in the last 3 months with the following products: • Replagal (agalsidase alfa) • Fabrazyme (agalsidase beta) • Galafold (migalastat) • Elfabrio (pegunigalsidase alfa) • VPRIV (velaglucerase alfa) • Cerezyme (imiglucerase) • Cerdelga (eliglustat) • Zavesca (miglustat) • Myozyme (alglucosidase alfa) • Nexviadyme (avalglucosidase alfa) • Pombiliti + Opfolda (cipaglucosidase alfa + miglustat) Q4. Do you participate in any clinical trials for Fabry(-Anderson) disease? If so, can you please provide the name of each trial along with the number of patients taking part? Q5. Do you participate in any clinical trials for Gaucher disease? If so, can you please provide the name of each trial along with the number of patients taking part?

Date of Response: 03/09/2026
View Response: 11812.pdf

Freedom of Information Request Reference: 11811

Date Received: 06/08/2026

Summary:
How many patients are on the waiting list to be seen for hip and knee replacements in each of the last five financial years, including this year? What are the average and longest waits for patients, by year? How many patients have waited over the waiting time target, by year? How many patients have waited over a year, by year? What is the waiting time for a new patient? How many hip and knee surgeons and how many surgeon vacancies do you have in your health board?

Date of Response: 10/09/2026
View Response: 11811.pdf

Freedom of Information Request Reference: 11810

Date Received: 06/08/2026

Summary:
How many patients are on the waiting list to be seen for Glaucoma treatment in each of the last five financial years, including this year? What are the average and longest waits for patients, by year? How many patients have waited over the 12 week waiting time target, by year? How many patients have waited over a year, by year? What is the waiting time for a new patient? How many Glaucoma Consultants and how many consultant vacancies do you have in your health board?

Date of Response: 04/09/2026
View Response: 11810.pdf

Freedom of Information Request Reference: 11808

Date Received: 05/08/2026

Summary:
For the most recent date for which data are available, please provide: 1. Current HCL Users • The number of people with Type 1 diabetes currently using a Hybrid Closed Loop system funded by the NHS within your Health Board area. • The number of people with Type 1 diabetes currently using a stand-alone pump funded by the NHS within your Health Board area. • Please provide these figures separately for: o Children and young people (aged under 18 years); and o Adults (aged 18 years and over) o How many have been onboarded through national/local means 2. Waiting List for HCL • The number of people with Type 1 diabetes who have been assessed as suitable for, eligible for, or approved for a Hybrid Closed Loop system but who are not yet receiving one. • Please provide this figure separately for: o Children and young people (aged under 18 years); and o Adults (aged 18 years and over). o Please include priority vs non-priority • The following details relating to waiting list for access to HCL systems, please provide: o The current number of people on the waiting list; o The longest waiting time; o When someone is put on the waiting list now, how long are they expected to wait o What is your priority criteria 3. Funding and Implementation • Following the Cabinet Secretary's letter to NHS Board Chief Executives, sent 29th May 2026 regarding funding for Hybrid Closed Loop system consumables and the incorporation of closed loop funding into NHS Board baselines for 2026/27, please provide: o The current number of HCL systems that you intend to initiate in 2026/7 o How does this compare with 2025/6 and 2024/5 o For 2026/27, what is estimated to be the proportion of total pump starts that will be ’non-priority’ patients o Does the Health Board have a strategic plan to determine the number of HCL starts over the next 5 years

Date of Response: 02/09/2026
View Response: 11808.pdf

Freedom of Information Request Reference: 11807

Date Received: 05/08/2026

Summary:
Q1. How many patients have been treated (for any condition) in the last 4 months with: •Benralizumab •Dupilumab •Omalizumab •Reslizumab •Mepolizumab •Tezepelumab Q2. How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with: •Dupilumab •Omalizumab Q3. How many patients have been treated in the last 4 months for Chronic Obstructive Pulmonary Disease (COPD) with: •Dupilumab •Mepolizumab

Date of Response: 02/09/2026
View Response: 11807.pdf

Freedom of Information Request Reference: 11806

Date Received: 04/08/2026

Summary:
1. The longest length in time in weeks that adults have had to wait for a tooth extraction in a) 2024/25 and b) 2025/26. 2. The average length in time in weeks that adults have had to wait for a tooth extraction in a) 2024/25 and b) 2025/26. 3. The longest length in time in weeks that children under 18 have had to wait for a tooth extraction in a) 2024/25 and b) 2025/26. 4. The average length in time in weeks that children under 18 have had to wait for a tooth extraction in a) 2024/25 and b) 2025/26.

Date of Response: 07/09/2026
View Response: 11806.pdf

Freedom of Information Request Reference: 11805

Date Received: 04/08/2026

Summary:
1) Are patients that are diagnosed with brain tumours within your NHS Board area given any brain tumour-specific dietary advice while undergoing treatment/management for their condition? If so, what is this advice? 2) Are patients that are diagnosed with brain tumours within your NHS Board area given any brain tumour-specific dietary advice that recommends a ketogenic (very low carbohydrate, high fat) approach?

Date of Response: 04/09/2026
View Response: 11805.pdf

Freedom of Information Request Reference: 11804

Date Received: 04/08/2026

Summary:
Please provide the following information for the period 1 January 2025 to the present month (August 2026) where possible, or January 2026 where data up until August is not available: 1. The number of patients for whom your organisation has arranged, funded, or reimbursed travel outside Scotland (including to England) for abortion services. 2. The number of patients referred to independent sector providers, such as, but not limited to the British Pregnancy Advisory Service (BPAS) for abortion care. Where it is possible to name the provider, please do. 3. The total annual amount paid by your organisation to independent sector providers for abortion services. If possible, please distinguish between: • Procedure/treatment costs • Administrative or contractual fees 4. The total annual cost incurred by your organisation in funding or reimbursing: • Patient travel (e.g. flights, rail, taxis) • Accommodation • Subsistence or related expenses

Date of Response: 10/09/2026
View Response: 11804.pdf

Freedom of Information Request Reference: 11803

Date Received: 04/08/2026

Summary:
1. Please provide me with the monthly cost to your board for supplying staff to the walk in centre in your board area 2. Please provide me with the number of staff there is per walk in centre 3. Please confirm if the walk in centre has had to be closed at any time due to staff absence or insufficient levels of staff 4. If the answer to 3 is yes, please confirm how many times the centre has been closed.

Date of Response: 08/09/2026
View Response: 11803.pdf

Freedom of Information Request Reference: 11802

Date Received: 04/08/2026

Summary:
Please send me the most recent Matched Job Report for the NHS Lothian Band 6 School Staff Nurses (non-SCPHN) and their current new Job Description, so I can see precisely how their job has now been re-evaluated at Agenda for Change Band 6 from Band 5 without having a Masters level SCPHN qualification. Please also let me how much back pay they are receiving. Please also send the JE5 Job Evaluation request form that was approved by managers with names redacted. Are they able to be called "school nurses" under NMC protected title rules? What is their current job title.

Date of Response: 01/09/2026
View Response: 11802.pdf

Freedom of Information Request Reference: 11801

Date Received: 04/08/2026

Summary:
Request in relation to robotic surgery systems procurement.

Date of Response: 01/09/2026
View Response: 11801.pdf

Freedom of Information Request Reference: 11788

Date Received: 29/07/2026

Summary:
Could you supply all costs so far of running the Wester Hailes GP walk-in centre, with a full breakdown of these costs? How many GPs are hired there, with breakdown of costs for them?

Date of Response: 04/09/2026
View Response: 11788.pdf

Freedom of Information Request Reference: 11785

Date Received: 30/07/2026

Summary:
I request the following recorded information: 1. Copies of any funding agreement or service level agreement between NHS Lothian and LGBT Health and Wellbeing in force during financial year 2024-25, including any schedule of agreed activities. 2. Recorded data showing total sums paid by NHS Lothian to that organisation in each of the financial years 2022-23, 2023-24, 2024-25 and 2025-26. 3. Copies of any guidance, policy, protocol, care pathway or patient information material held by NHS Lothian relating to induced lactation or lactation induction in non-gestational parents. 4. The current formulary status within NHS Lothian of domperidone when used to induce or augment lactation, together with copies of any Area Drug and Therapeutics Committee papers or minutes in which that use was considered, for the period January 2020 to the present. 5. Copies of any evidence appraisal, literature review or clinical governance assessment held by NHS Lothian in relation to the material requested at points 3 and 4.

Date of Response: 11/09/2026
View Response: 11785.pdf

Freedom of Information Request Reference: 11778

Date Received: 28/07/2026

Summary:
Please provide the following information for the latest 12-month period available relating to the use of 4% chlorhexidine gluconate (CHG) products within your Trust. For all 4% chlorhexidine products used for patient decolonisation, skin antisepsis, surgical hand antisepsis or surgical scrubbing, please provide: • Product brand name • Manufacturer/supplier • Pack size • Total quantity purchased during the period (units, bottles, litres, cartridges, sachets, etc.) • Total annual spend (£)

Date of Response: 10/09/2026
View Response: 11778.pdf

Freedom of Information Request Reference: 11777

Date Received: 28/07/2026

Summary:
1. The total amount of funding provided by NHS Lothian to LGBT Health and Wellbeing in each of the financial years 2022/23, 2023/24, 2024/25 and 2025/26 to date. Of the above funding, any amounts specifically allocated to, or used to support, the “Queer Milk” group or any programme promoting or facilitating chestfeeding / induced lactation by biological males for the purpose of infant feeding. 2. Copies of any risk assessments, clinical evidence reviews, child impact assessments, or safeguarding assessments carried out by or for NHS Lothian in relation to supporting or funding male lactation / chestfeeding for infant feeding. 3. Details of any contractual or service-level agreements between NHS Lothian and LGBT Health and Wellbeing that cover infant feeding, breastfeeding, or chestfeeding support, including any requirements relating to clinical standards or child safeguarding. Details of any assessment undertaken of how such funding or support complies with: 4. NHS Lothian’s duties under a. the Children (Scotland) Act 1995 (welfare of the child as paramount); b. the United Nations Convention on the Rights of the Child (Incorporation) (Scotland) Act 2024 (best interests of the child as a primary consideration); and c. the principles of Getting It Right for Every Child (GIRFEC), particularly the requirement that the child’s wellbeing remains central to decision-making.

Date of Response: 10/09/2026
View Response: 11777.pdf

Freedom of Information Request Reference: 11766

Date Received: 27/07/2026

Summary:
Please provide the following information regarding the utilisation of external outsourcing, internal insourcing, and capacity management strategies for adult urology services, specifically concerning the current 507-patient backlog for therapeutic circumcision: Part 1: Independent Sector Outsourcing and Frameworks 1. Independent Sector Expenditure: Over the last two financial years (2024/25 and 2025/26), what has been the total financial expenditure by NHS Lothian specifically on outsourcing adult therapeutic circumcisions or phimosis-related procedures to Independent Sector Providers (ISPs) or private treatment centres? 2. National Framework Utilisation: Does NHS Lothian utilise National Procurement Scotland (NSS) framework agreements or local independent sector contracts to commission capacity for adult elective circumcisions / phimosis-related procedures? If yes, what exact volume of patients requiring this specific procedure has been contracted or outsourced through these frameworks over the last 12 months? 3. Contracted Pathway Specifics: Do any current outsourcing contracts with independent providers for adult circumcision mandate specific outpatient local anaesthetic (LA) pathways or modern device technologies (such as disposable circular staplers), or are procedures commissioned exclusively on a general-anaesthetic main-theatre basis? Part 2: Internal Insourcing and Additional List Management 4. Weekend and Evening Insourcing: Does the Board currently deploy internal "insourcing" teams (utilising existing NHS staff working additional evening or weekend shifts paid at enhanced rates) to clear the urology waiting list? 5. Insourcing Volume: If internal insourcing is utilised, how many adult therapeutic circumcisions were performed via dedicated insourcing sessions over the last 12 financial months (June 2025 – June 2026)? 6. Capacity Modeling: Given that NHS Lothian has confirmed a waiting list of 507 patients with a median wait time of 308.5 days (over 44 weeks) for therapeutic circumcision, what specific capacity modeling or recovery plan does the Board hold to bring performance back within the statutory 12-week Treatment Time Guarantee mandated by the Patient Rights (Scotland) Act 2011? Part 3: Operational Bottlenecks and Theatre Utilisation 7. Ring-Fenced Ambulatory Capacity: Has the Board evaluated or established any ring-fenced, dedicated ambulatory day-case slots for minor soft-tissue urological procedures outside of high-overhead main operating suites? If not, please provide the rationale explaining how a 507-patient queue is managed while maintaining traditional main-theatre constraints.

Date of Response: 10/09/2026
View Response: 11766.pdf

Freedom of Information Request Reference: 11758

Date Received: 23/07/2026

Summary:
For each of the financial years 2021/22, 2022/23, 2023/24, 2024/25 and 2025/26, please provide: 1. The number of NHS staff who recorded at least one period of sickness absence due to anxiety, stress, depression or other mental illness (ASDOM). 2. The total number of working days lost due to staff sickness absence recorded under ASDOM. 3. The longest single shift worked by any member of staff in each year. For the purposes of this request, by “shift” I mean the continuous period between a member of staff starting and finishing work, including any recorded overtime or additional hours worked immediately before or after their scheduled shift. For question 3, please also provide the length of the shift and the staff group or role of the employee concerned, where this can be provided without identifying the individual. For 2025/26, please provide the final full-year figures where available, or the most up-to-date figures held if these have not yet been finalised.

Date of Response: 03/09/2026
View Response: 11758.pdf

Freedom of Information Request Reference: 11752

Date Received: 22/07/2026

Summary:
I would be grateful if you could provide the following: 1. Local policies and procedures a) The current grievance and bullying/harassment policy applicable to staff and trainees within NHS Lothian, and the version in force between January and July 2026. b) The current occupational health referral policy, and any policy governing how reasonable adjustment requests raised via occupational health are recorded, escalated and actioned. c) The current Freedom to Speak Up (or equivalent whistleblowing) policy applicable within the relevant directorate. d) Any local Equality Impact Assessment carried out in relation to workforce or trainee-related decisions within the Obstetrics and Gynaecology and Paediatrics & Neonatology department, in the last twenty years. 2. Aggregate, anonymised statistics (last twenty years, or since records began if shorter) a) The number of formal grievances or discrimination complaints raised by staff or trainees within the Obstetrics and Gynaecology and Paediatrics & Neonatology department, and their outcomes. b) The number of occupational health referrals relating to disability or reasonable adjustments within the Obstetrics and Gynaecology and Paediatrics & neonatology department, and how many resulted in adjustments being implemented versus declined, where this data is held. c) Staff survey or culture survey results (e.g. NHS Staff Survey or local equivalent) broken down by department, specifically for Obstetrics and Gynaecology, relating to questions on discrimination, bullying, harassment, or fairness of treatment, for the last five years. d) Any data held on staff turnover or exit reasons within the Obstetrics and Gynaecology and Paediatrics & Neonatology department, broken down by ethnicity and disability status where this is recorded. 3. Prior complaints, reports and reviews a) Any formal complaints, Freedom to Speak Up submissions, or whistleblowing reports relating to the culture, management, or conduct of staff within the Obstetrics and Gynaecology and Paediatrics & Neonatology department in the last twenty years. I understand you may need to redact the names of complainants or other individuals, and I am content to receive redacted versions. b) Any internal or external review, audit, or inspection report relating to workplace culture, bullying, or discrimination within the Obstetrics and Gynaecology & Paediatrics & Neonatology department in the last twenty years. 4. Governance a) Whether staff and managers within the Obstetrics and Gynaecology and Paediatrics & Neonatology department have received unconscious bias, equality and diversity, or reasonable adjustment training, and the dates of any such training. b) Terms of reference and membership of any local committee or panel involved in raising or resolving workplace grievances within the department.

Date of Response: 11/09/2026
View Response: 11752.pdf

Freedom of Information Request Reference: 11744

Date Received: 20/07/2026

Summary:
1. Flexible Bronchoscopy Procedures Please provide the total number of flexible bronchoscopy procedures performed across NHS Lothian during the most recent full financial year. I request that this data be broken down by: • Hospital site • Department / clinical area (e.g., ICU, Respiratory, Theatres, ED, etc.) 2. Disposable Bronchoscope Expenditure Please provide the total spend on disposable flexible bronchoscopes for the last 12 months (or most recent 12 month period available). Again, please break this down by: • Hospital site • Department / clinical area

Date of Response: 03/09/2026
View Response: 11744.pdf

Freedom of Information Request Reference: 11695

Date Received: 08/07/2026

Summary:
1. The number of people with a learning disability that the health board recognises as eligible for a health check. 2. The number of those people with a learning disability who have been offered a health check to present date. Please also provide the number as a % of overall number of people. 3. The number of those people who have received a health check upon accepting an offer to present date. Please also provide the number as a % of overall number of people. 4.The number of eligible people who have not: (i) been offered one health check since the checks began; (ii) accepted one health check since the checks began. Please also provide the number as a % of overall number of people. 5. The total amount of money the health board has received from the Scottish Government in each financial year since the inception of checks to provide health check sot people with learning disabilities.

Date of Response: 11/09/2026
View Response: 11695.pdf

Freedom of Information Request Reference: 11683

Date Received: 07/07/2026

Summary:
1. How many care packages is your ICB currently commissioning on a spot-purchase basis from providers who are on an organised framework agreement or Dynamic Purchasing System (DPS)? Please break this down by: o HCA-led packages o Registered Nurse-led packages 2. What is the average charge rate for the spot-purchased packages identified in question 1? Please provide the average hourly rate (or other applicable unit) broken down by HCA-led and Registered Nurse-led packages. 3. For the spot-purchased packages identified in question 1, are any additional fees charged in addition to the standard hourly rate (for example: invoice processing fees, bank holiday premiums, mileage or travel costs, administration fees, out-of-hours supplements)? If yes, please provide full details of these fees and how they are applied. 4. Please list all providers currently used by your ICB to deliver care packages on a spot-purchase basis. 5. Please list all framework agreements and Dynamic Purchasing Systems (DPS) currently in place within your ICB for the commissioning of care packages. For each framework or DPS, please indicate: o Whether it is divided into lots (e.g. by geography or service type) o Whether any mandatory, maximum or minimum rates are attached to the framework/DPS or to individual lots. If yes, please provide the rates. 6. How many care packages is your ICB currently commissioning via call-off contracts or other arrangements under the frameworks and DPS listed in question 5 (i.e. not on a spot-purchase basis)? 7. For each framework or DPS currently in place, how many providers have a place on it?

Date of Response: 02/09/2026
View Response: 11683.pdf

Freedom of Information Request Reference: 11660

Date Received: 01/07/2026

Summary:
I'm seeking a usage report for single-use diathermy electrodes, single-use smoke evacuation pencils, and smoke evacuation machines across all hospitals/sites in your trust for the last completed financial year (1 April 2025 – 31 March 2026). If readily available, please also include the current financial year to date (from 1 April 2026). -Trust site / hospital -Product code -Description -Manufacturer name and brand (if held) -Supplier (e.g., NHS Supply Chain or direct supplier) -Pack size & unit of measure -Quantity usage -Total spend for each product

Date of Response: 11/09/2026
View Response: 11660.pdf

Freedom of Information Request Reference: 11866

Date Received: 28/08/2026

Summary:
Request in relation to communication records.

Date of Response: 31/08/2026
View Response: 11866.pdf

Freedom of Information Request Reference: 11847

Date Received: 20/08/2026

Summary:
Request in relation to personal information.

Date of Response: 21/08/2026
View Response: 11847.pdf

Freedom of Information Request Reference: 11800

Date Received: 03/08/2026

Summary:
Q1. How many patients were treated in the last 4 months (April to July 2026) by the dermatology department with each of the following products: • Abrocitinib • Acitretin • Alitretinoin • Azathioprine • Baricitinib • Ciclosporin • Dupilumab • Lebrikizumab • Methotrexate • Mycophenolate mofetil • Pimecrolimus • Phototherapy (UVB or PUVA) - for Atopic Dermatitis only • Tacrolimus ointment • Tralokinumab • Upadacitinib • Nemolizumab Q 2. In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department • Abrocitinib • Baricitinib • Dupilumab • Lebrikizumab • Tralokinumab • Upadacitinib • Nemolizumab *Patients are considered initiated if they have not been treated in the previous 8 months with any of the drugs that are part of the named regimen Q3. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group: • 6 months to 5 • Age 6-11 • Age 12-17 • Age 18 and above Q4. How many patients have received treatment by the dermatology department for Prurigo Nodularis in the last 4 months with each of the following products: • Dupilumab • Nemolizumab

Date of Response: 31/08/2026
View Response: 11800.pdf

Freedom of Information Request Reference: 11798

Date Received: 03/08/2026

Summary:
• Spend on Insourcing from May 2026-end of July 2026, broken down by each specialty and subspecialty, and the insourcing company that was used, e.g. cardiology £1000- echo cardiogram £1000- company x £1000 • The budget for each specialty for insourcing • Confirm the contract start and end date for each specialty • What frameworks were used for each specialty and was there direct awards and if so, who was they awarded to and what specialty • What was the service, e.g. theatres, outpatient, or diagnostic

Date of Response: 31/08/2026
View Response: 11798.pdf

Freedom of Information Request Reference: 11797

Date Received: 03/08/2026

Summary:
Please could I request data regarding patient initiations on all Scottish Medicines Consortium (SMC) approved biologic therapies for severe asthma. Specifically, please could you provide the total number of patients initiated on the following respiratory biologic medications, broken down by month for the time period of Jan-24 to Jul-26. Benralizumab (Fasenra) Dupilumab (Dupixent) Mepolizumab (Nucala) Omalizumab (Xolair / Omlyclo) Tezepelumab (Tezspire)

Date of Response: 31/08/2026
View Response: 11797.pdf

Freedom of Information Request Reference: 11796

Date Received: 03/08/2026

Summary:
To ask how many health board staff currently are listed as having their main residence outside Scotland. Could you disclose how many employees have their address in England, Wales or Northern Ireland. In addition, if any staff live mainly outside of the UK, could you please disclose the country of their residence. Finally, if you hold the information, could you state how many staff lived outside of Scotland in the following years: 2025/26 2024/25 2023/24

Date of Response: 28/08/2026
View Response: 11796.pdf

Freedom of Information Request Reference: 11795

Date Received: 03/08/2026

Summary:
In the period 1st May 2026 to 31st July 2026 please provide a breakdown of: • Total trust spend with framework agencies for locum doctors Please provide a further breakdown for locum doctors by: • Spend per grade • Spend per specialty • Spend per agency name   In the period 1st May 2026 to 31st July 2026 please provide a breakdown of: • Total trust spend with off-framework agencies for locums doctors Please provide a further breakdown for locum doctors by: • Spend per grade • Spend per specialty • Spend per agency name   In the period 1st May 2026 to 31st July 2026 please provide a breakdown of: • Total trust spend with the internal trust bank or associated external provider for locum doctors Please provide a further breakdown for locum doctors by: • Spend per grade • Spend per specialty • Spend per internal or associated external provider Please confirm your allocated budget for agency locum doctors for the period 1st May 2026 to 31st July 2026 Please confirm the name of the framework used for the supply of locum doctors in your trust.

Date of Response: 31/08/2026
View Response: 11795.pdf

Freedom of Information Request Reference: 11794

Date Received: 24/07/2026

Summary:
The links to the following guidelines below are shown on the Hypertension & Lipid Services landing page https://apps.nhslothian.scot/refhelp/guidelines/hypertensionandlipidservices/ However they appear to be on an intranet system, rather than the publicly available one, I wonder if you would be kind enough to send me a copy of each? https://apps.nhslothian.scot/refhelp/approach-to-statin-associated-adverse-effects/ https://apps.nhslothian.scot/refhelp/1-assessment/ https://apps.nhslothian.scot/refhelp/faqs/ https://apps.nhslothian.scot/refhelp/lipid-lowering-medication-in-specific-patient-groups/ https://apps.nhslothian.scot/refhelp/lipids/ https://apps.nhslothian.scot/refhelp/suspected-inherited-lipid-disorders-including-familial-hypercholesterolaemia/

Date of Response: 24/08/2026
View Response: 11794.pdf

Freedom of Information Request Reference: 11793

Date Received: 03/08/2026

Summary:
1. Please provide a copy of every current document that records a standard rate your board pays for ad hoc consultant-grade work or on-call cover outside the programmed activities of a substantive job plan. Please include arrangements known as staff bank, medical bank, internal locum, extra-contractual work, additional hours at a separate or locally enhanced rate, waiting-list or additional activity work, or any other alternative payment arrangement - the label does not matter. I am not asking for agency invoices, ordinary extra programmed activities paid at the national contractual rate, or individual payment records. 2. Where a rate covered by item 1 is not fully stated in those documents, please provide the recorded rate from wherever it is held. For each rate, please state: the grade it applies to, your board's own day and time categories, any speciality or site restriction, the payment mechanism, whether an annual leave supplement is included, and the date it took effect. If your board has no standard rate, please say so and provide any recorded formula, default, minimum, maximum or approval limit used instead. 3. Please provide the recorded rules on whether a doctor or dentist holding a substantive post with your board may also register for, work, and be paid for ad hoc consultant-grade shifts for the same board, under any of the mechanisms in item 1. Please include the relevant policy, bank terms, contract terms or approval procedure. If prior approval is needed, please say which role approves and on what conditions. If no document answers the question directly, please provide the recorded terms your board would use to decide. 4. For the rates you provide, please give: (a) the date each took effect, (b) the date and outcome of the most recent review of them, including a review that changed nothing, and (c) any replacement rate already approved but not yet in force, with its planned start date. I am not asking for anything created after you receive this request.

Date of Response: 28/08/2026
View Response: 11793.pdf

Freedom of Information Request Reference: 11792

Date Received: 03/08/2026

Summary:
I understand that a team of consultants were tasked with assessing the cladding on the new Royal Hospital for Children and Young People in the wake of the Grenfell Tower disaster. Can I get a copy of their final report which was submitted to NHS Lothian health board please? I think this was submitted to the board in or around January 2022. can I also ask whether the 3% daylight factor required by the contract for the childrens bedrooms was achieved for any of the 4 bedroom wards in the Royal Hospital for Children and Young People?

Date of Response: 28/08/2026
View Response: 11792.pdf

Freedom of Information Request Reference: 11791

Date Received: 03/08/2026

Summary:
Regarding the job banding and grading of the Resilience Head role within your organisation. Please provide the following information: 1. The current job band/grade assigned to the Resilience Head role. 2. The date on which the current banding or grading decision was made and how this compares to neighbouring NHS boards with the equivalent role. 3. The job evaluation or grading framework used to determine the role’s banding 4. A copy of the role profile/job description used for the evaluation (with any appropriate redactions applied if required). 5. The factors, criteria, or scoring outcomes that informed the banding decision. 6. Details of any review, reassessment, or challenge of the role’s banding since it was established.

Date of Response: 28/08/2026
View Response: 11791.pdf

Freedom of Information Request Reference: 11790

Date Received: 03/08/2026

Summary:
To ask what the total energy bill for your health board was in the following financial years. If possible, could this be broken down by gas and electricity. 2021/22 2022/23 2023/24 2024/25 2025/26

Date of Response: 31/08/2026
View Response: 11790.pdf

Freedom of Information Request Reference: 11789

Date Received: 31/07/2026

Summary:
1. Existing Aquariums Please confirm whether the Trust currently owns or operates any ornamental aquarium(s) or aquatic displays. If yes, please provide: The number of aquariums currently in operation. Their general location (e.g. reception, children's ward, outpatient department, waiting area). The approximate year each aquarium was installed. 2. Installation Supplier For each aquarium, please provide: The company that supplied and/or installed the aquarium. Whether the installation was procured via a tender or procurement framework or a direct award (and, if applicable, the name of the framework). 3. Maintenance Please confirm: Whether aquarium maintenance is carried out in-house or by an external contractor. If externally maintained: Name of the contractor. Contract start date. Contract expiry or renewal date. Approximate annual contract value. 4. Future Projects Please confirm whether the Trust currently has any plans, approved projects or budget allocations for new aquarium installations, replacements or refurbishments within the next 24 months. 5. Procurement Please provide: The department responsible for procuring aquarium installations and maintenance. The job title of the person or team responsible. 6. Expenditure Please provide, where available: Total expenditure on aquarium installations over the previous five financial years. Annual expenditure on aquarium maintenance for each of the previous five financial years. 7. Supporting Documentation Please provide copies of any business cases, reports, evaluations or studies relating to the installation of aquariums, including any documents discussing patient wellbeing, staff wellbeing, visitor experience or therapeutic benefits.

Date of Response: 28/08/2026
View Response: 11789.pdf

Freedom of Information Request Reference: 11786

Date Received: 30/07/2026

Summary:
I am interested in work about NHS finances carried out for the Scotland East region. Please provide all papers, meeting minutes and other documents covering the Scotland East region’s finances. This would include but is not limited to modelling, financial outlook, options for savings, papers presented at meetings, minutes and agendas, etc.

Date of Response: 28/08/2026
View Response: 11786.pdf

Freedom of Information Request Reference: 11783

Date Received: 29/07/2026

Summary:
Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2026 and end of June 2026? 1.1 Benralizumab (Fasenra) 1.2 Depemokimab (Exdensur) 1.3 Dupilumab (Dupixent) 1.4 Mepolizumab (Nucala) 1.5 Omalizumab (Xolair) 1.6 Reslizumab (Cinqaero) 1.7 Tezepelumab (Tezspire) Q2. How many patients were treated for severe asthma, COPD, CRwNP with the following medicines in the 3 months between the start of April 2026 and end of June 2026? 2.1 Benralizumab (Fasenra) 2.2 Depemokimab (Exdensur) 2.3 Dupilumab (Dupixent) 2.4 Mepolizumab (Nucala) 2.5 Omalizumab (Xolair) 2.6 Reslizumab (Cinqaero) 2.7 Tezepelumab (Tezspire) Q3. How many patients were treated for Atopic Dermatitis with the following medicines in the 3 months between the start of April 2026 and end of June 2026? 3.1 Dupilumab (Dupixent) Q4. How many patients were treated by department in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2026 and end of June 2026? 4.1 Benralizumab (Fasenra) 4.2 Depemokimab (Exdensur) 4.3 Dupilumab (Dupixent) 4.4 Mepolizumab (Nucala) 4.5 Omalizumab (Xolair) 4.6 Reslizumab (Cinqaero) 4.7 Tezepelumab (Tezspire)

Date of Response: 27/08/2026
View Response: 11783.pdf

Freedom of Information Request Reference: 11782

Date Received: 29/07/2026

Summary:
Q1. How many patients were treated in total regardless of diagnosis with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data? Adalimumab Etrasimod Filgotinib Golimumab Guselkumab Infliximab Mirikizumab Ozanimod Risankizumab Tofacitinib Upadacitinib Ustekinumab Vedolizumab Q2. How many patients were treated by the Gastroenterology Department or Clinic with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data? Adalimumab Etrasimod Filgotinib Golimumab Guselkumab Infliximab Mirikizumab Ozanimod Risankizumab Tofacitinib Upadacitinib Ustekinumab Vedolizumab Q3. How many patients with Crohn’s Disease, Ulcerative Colitis or Inflammatory Bowel Disease NOS in total regardless of department / clinic, were treated with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data? Adalimumab Etrasimod Filgotinib Golimumab Guselkumab Infliximab Mirikizumab Ozanimod Risankizumab Tofacitinib Upadacitinib Ustekinumab Vedolizumab

Date of Response: 27/08/2026
View Response: 11782.pdf

Freedom of Information Request Reference: 11781

Date Received: 29/07/2026

Summary:
Q1. How many patients were treated in total regardless of diagnosis with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data? Adalimumab Abrocitinib Apremilast Baricitinib Bimekizumab Brodalumab Certolizumab Pegol Deucravacitinib Dupilumab Etanercept Guselkumab Infliximab Ixekizumab Lebrikizumab Nemolizumab Risankizumab Secukinumab Tildrakizumab Tralokinumab Ustekinumab Q2. How many patients were treated by the Dermatology or Rheumatology Departments or Clinics with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data? Adalimumab Apremilast Baricitinib Bimekizumab Brodalumab Certolizumab Pegol Etanercept Guselkumab Infliximab Ixekizumab Risankizumab Secukinumab Ustekinumab Q3. How many patients with Plaque Psoriasis or Psoriatic Arthritis across all departments were treated with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data? Adalimumab Bimekizumab Secukinumab Apremilast Certolizumab Pegol Etanercept Guselkumab Infliximab Ixekizumab Risankizumab Ustekinumab Brodalumab Deucravacitinib Q4. How many patients with Atopic Dermatitis across all departments were treated with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data? Baricitinib Dupilumab Nemolizumab Q5. How many patients with Hidradenitis Suppurativa across all departments were treated with the following drugs between 1st April 2026 and 30th June 2026, or the latest 3-month period for which you have data? Adalimumab Bimekizumab Secukinumab

Date of Response: 27/08/2026
View Response: 11781.pdf

Freedom of Information Request Reference: 11780

Date Received: 29/07/2026

Summary:
1. Please provide me with a breakdown of how many patients came into the walk in centre in your board area and registered as a ‘case’ each day since the centre opened. 2. Please confirm if there have been any days, since the centre opened, where no patients have come in and how many days this has happened.

Date of Response: 24/08/2026
View Response: 11780.pdf

Freedom of Information Request Reference: 11779

Date Received: 29/07/2026

Summary:
I am writing to formally request an internal review of the decision regarding FOI request 11643. In your response dated 28 July 2026, the Board claimed it does not hold administrative email addresses for GP practices, stating it only communicates via "individuals or clinical mailboxes". I am challenging the assertion that administrative contact information is "not held" and the subsequent blanket withholding of this data. While I acknowledge that clinical mailboxes used solely for patient data should not be disclosed, the Board inevitably uses electronic endpoints to communicate operationally with independent GP contractors (e.g., sending contract updates, public health directives, and administrative notices). If the Board routes this administrative communication to the direct email addresses of Practice Managers (the "individuals" mentioned in your response), then those endpoints function as the main administrative contacts and fall squarely within the scope of my request. If the Board considers a Practice Manager's email address to be exempt personal data under Section 38(1)(b) of FOISA because it contains their name, the correct legal procedure is not to issue a blanket refusal or claim the data is "not held." Instead, the Board has a duty to redact the identifying elements of the email string (e.g., providing [Redacted]@nhslothian.scot.nhs.uk) to disclose the functional administrative routing information while protecting the individual's identity. Practice Managers are senior administrative officials managing publicly funded contracts; their official business contact routes carry a low expectation of absolute privacy when balanced against the public interest of transparency. I request that you conduct a thorough internal review, identify the electronic endpoints used for non-clinical, operational communication with these practices, and release them, applying redactions to purely personal identifiers where strictly necessary.

Date of Response: 31/08/2026
View Response: 11779.pdf

Freedom of Information Request Reference: 11776

Date Received: 27/07/2026

Summary:
1) How many complaints have NHS Lothian received against the Western General Hospital regarding the treatment provided by Mammographer's for the years 2023 to 26 itemised for each year. 2) How many complaints have NHS Lothian received against the mobile units within NHS Lothian regarding the treatment provided by Mammographer's for the years 2023 to 26 itemised for each year. 3) How many complaints have NHS Lothian received against Ardmillan House regarding the treatment provided by Mammographer's for the years 2023 to 26 itemised for each year.

Date of Response: 24/08/2026
View Response: 11776.pdf

Freedom of Information Request Reference: 11775

Date Received: 29/07/2026

Summary:
• In year 25/26, how many hours were lost / given in Lothian to Paternity Leave? (Also known as "New parent support leave") [outlined in section 15.0 AfC} • In year 25/26, how many hours were lost / given in Lothian to Maternity Leave? Additionally: • How many staff as a % of the workforce, identify as Male? • How many staff as a % of the workforce, identify as Female?

Date of Response: 28/08/2026
View Response: 11775.pdf

Freedom of Information Request Reference: 11774

Date Received: 28/07/2026

Summary:
1. Does the argument that it’s not “clinically safe” simply mean that there aren’t enough WTE consultants? 2. How many WTE consultants are required for treatment to be “clinically safe”? 3. The July 5th minute says that “recruitment continues”. What was the result of that recruitment? 4. Why has there been no additional recruitment? 5. Who decided that there should be no additional recruitment? 6. When was that decision last made? 7. I asked about approval by Lothian Health Board, not the Executive Leadership Team. Has this continuing non-treatment been approved by the Board? If so, when?

Date of Response: 27/08/2026
View Response: 11774.pdf

Freedom of Information Request Reference: 11773

Date Received: 28/07/2026

Summary:
What is the GP to patient ratio in Craiglockhart medical group please?

Date of Response: 25/08/2026
View Response: 11773.pdf

Freedom of Information Request Reference: 11771

Date Received: 27/07/2026

Summary:
I would be grateful if you could provide the following information regarding the NHS Lothian Adult ADHD Service: What month and year of adult ADHD diagnoses are currently being invited to begin medication titration? How many patients are currently waiting to start ADHD medication titration? What is the current median waiting time from diagnosis to the first titration appointment? What is the longest current wait from diagnosis to the first titration appointment? How many clinicians are currently authorised to prescribe and supervise ADHD medication titration within the adult service? If available, what is the estimated waiting time for a person diagnosed today to begin medication titration?

Date of Response: 25/08/2026
View Response: 11771.pdf

Freedom of Information Request Reference: 11770

Date Received: 27/07/2026

Summary:
Part A. General practice workforce vacancies 1. For each GP practice in your Board area, the number of vacant GP posts (headcount and whole-time equivalent) as at the most recent date for which information is held, and, where recorded, how long each post has been vacant. 2. If practice-level vacancy information is not held, any aggregate assessment of GP workforce vacancies across the Board area produced in the last 12 months, for example workforce planning reports or primary care strategy papers. Part B. Patient list closures and capacity 3. The number of applications or notifications from GP practices relating to closure of their patient lists, whether formal or informal (including managed or temporary closures and agreed restrictions on new registrations), received in each of the financial years 2024/25 and 2025/26 to date, and for each one the practice name, the date received, and the outcome (approved, refused, withdrawn, or agreed). 4. For each of the same financial years, the number of GP practices in your area that closed, merged, or terminated their General Medical Services contract, with the practice name and effective date in each case. 5. Any register or list currently maintained by the Board of practices whose patient lists are formally closed, or subject to agreed restrictions on new patient registrations, as at the date of this request. 6. Any list currently maintained by the Board of practices identified as requiring support with capacity or sustainability, for example through a primary care risk register or sustainability programme, as at the date of this request. If disclosing practice names would engage an exemption, please provide the information with practice identifiers redacted rather than refusing the item in full.

Date of Response: 25/08/2026
View Response: 11770.pdf

Freedom of Information Request Reference: 11769

Date Received: 27/07/2026

Summary:
Q1. How many total patients has the trust seen within the latest 24 months of available data (for any reason), with a recorded diagnosis of Dravet Syndrome (DS) Q2. Of total DS patients, how many have been treated with Epidyolex (Cannabidiol) in the last 12 months? Q3. Of total DS patients, how many have been treated with Fintepla (Fenfluramine) in the last 12 months? Q4. How many total patients has the trust seen within the latest 24 months of available data (for any reason), with a recorded diagnosis of Lennox-Gasteau Syndrome (LGS) Q5. Of total LGS patients, how many have been treated with Epidyolex (Cannabidiol) in the last 12 months? Q6. Of total LGS patients, how many have been treated with Fintepla (Fenfluramine) in the last 12 months? Q7. How many adult (aged 18+) patients has the trust seen within the latest 24 months of available data (for any reason), with a recorded diagnosis of Dravet Syndrome (DS) Q8. How many adult (aged 18+) patients has the trust seen within the latest 24 months of available data (for any reason), with a recorded diagnosis of Lennox-Gasteau Syndrome (LGS)

Date of Response: 27/08/2026
View Response: 11769.pdf

Freedom of Information Request Reference: 11768

Date Received: 27/07/2026

Summary:
I am writing to seek clarification regarding NHS Lothian's policy on wearing staff uniforms while travelling on public transport. Could you please advise whether staff are permitted to wear their uniform when commuting to and from work on public transport, and whether there are any specific guidelines or infection prevention requirements that should be followed? I would be grateful for any information or relevant policy documents you can provide.

Date of Response: 24/08/2026
View Response: 11768.pdf

Freedom of Information Request Reference: 11767

Date Received: 27/07/2026

Summary:
For the period 1 January 2023 to the date of this request, please provide: Copies of correspondence, briefings, reports, presentations, meeting records or advice exchanged with the Scottish Government, Healthcare Improvement Scotland, Public Health Scotland or another body concerning: a. the safety or regulation of non-surgical cosmetic procedures; b. restrictions upon which practitioners may perform specified procedures; c. requirements to operate from HIS-registered premises; d. the presence of an authorised prescriber or healthcare professional; and e. procedure classification or risk categorisation. The number of attendances, referrals or admissions recorded by the Board following complications or suspected complications from non-surgical cosmetic procedures, broken down where recorded by: a. financial or calendar year; b. procedure; c. type of complication; d. hospital, service or department; e. whether treatment was provided in Scotland; and f. whether the original procedure was performed in an NHS or private setting. For the records counted under point 2, the number attributed to procedures performed by: a. independent aesthetic practitioners; b. doctors; c. dentists; d. nurses or midwives; e. pharmacists; f. other statutory healthcare professionals; g. practitioners whose professional status was not recorded; and h. practitioners whose identity or status could not be verified. Aggregate figures are requested. No information identifying clients or individual practitioners is required. Copies of any coding guidance, data definitions, collection instructions or methodology used to identify: a. a non-surgical cosmetic procedure; b. a complication arising from such a procedure; c. the procedure performed; d. the setting in which it was performed; and e. the professional or registration status of the person who performed it. Copies of any analysis, audit, research, literature review or internal report comparing complication rates or outcomes between different practitioner or professional groups. Copies of any complication, injury, infection, referral or admission data supplied by the Board to the Scottish Government, HIS, Public Health Scotland, a parliamentary committee, an advisory group or another body for the purpose of developing or supporting the proposed legislation. Copies of requests received by the Board for evidence, data or professional advice concerning the Scottish Government consultation, the relevant Bill, procedure groupings, practitioner restrictions, premises requirements or proposed secondary legislation. Copies of any evidence, advice, recommendations or concerns submitted in response to the requests identified under point 7. Copies of records identifying NHS Board employees or representatives who attended or contributed to any government advisory group, expert group, workshop or meeting concerning the regulation of non-surgical cosmetic procedures. Please provide their job titles, the body or meeting attended and the dates of participation. Copies of any assessment of the expected effect of the legislation upon NHS services, including: a. changes in the number or severity of complications presented to the NHS; b. displacement of procedures into informal or unregulated settings; c. increased demand for corrective treatment; d. reduced reporting of complications; e. treatment availability in rural or island areas; and f. additional costs or staffing requirements for the Board. Copies of records received concerning the number or participation of practising independent aesthetic practitioners directly involved in developing the regulatory proposals, excluding people who only submitted an open public consultation response. Copies of records concerning the role, status, authority or representative standing of: a. the Joint Council for Cosmetic Practitioners; b. Save Face Limited; c. the Scottish Medical Aesthetics Safety Group; d. BABTAC; and e. the British Beauty Council. Copies of any correspondence or meeting records between the Board and an organisation listed in point 12 concerning non-surgical cosmetic procedures, practitioner competence, complication reporting, referrals, public guidance or Scottish regulation.

Date of Response: 25/08/2026
View Response: 11767.pdf

Freedom of Information Request Reference: 11765

Date Received: 27/07/2026

Summary:
Please could you provide the Whole Time Equivalent (WTE) numbers for the following medical staffing categories within your Health Board: 1. Consultants 2. Associate Specialists (or the current equivalent grade under the SAS contract reform) 3. Specialty Doctors 4. Foundation Year 1 (FY1) and Foundation Year 2 (FY2) Doctors (either separately or combined) Please provide this data annually for the years 2022, 2023, 2024, 2025, and 2026.

Date of Response: 28/08/2026
View Response: 11765.pdf

Freedom of Information Request Reference: 11764

Date Received: 24/07/2026

Summary:
Please provide the annual test volumes for your most recent complete reporting period, either Financial Year (e.g. 2025/26) or Calendar Year (2025).

Date of Response: 24/08/2026
View Response: 11764.pdf

Freedom of Information Request Reference: 11763

Date Received: 23/07/2026

Summary:
I am writing to request the recorded information set out below regarding the Trust’s histopathology services. Where any figure is not held in the exact form requested, I would be grateful for the nearest available data together with a note of the basis on which it is provided: 1. What was your total histopathology department case volume for in each of the two most recent completed financial years (FY24/25 and FY25/26) and the % of each which was digital? Please provide the number of final cases (as opposed to slides, blocks or specimens). 2. Of that volume, how many cases were reported in-house versus outsourced to an external provider in each year, and which external provider(s) were used? 3. For outsourced histopathology work, please break down volume and spend according to whether the provider performed the full laboratory process as well as reporting (wet and report), or provided reporting only with the Trust performing all laboratory processing (report only). 4. For each provider used, please confirm the method of case transfer (glass slide delivery or digital transfer). 5. For each provider used, please confirm the method of report delivery (email/PDF, secure reporter access to local pathology system, separate provider portal, electronic automation into local pathology system). 6. What percentage of histopathology cases were reported within 7, 10 and 14 calendar days of receipt over the most recent 12-month period (measured against Royal College of Pathologists key performance indicators)? 7. For outsourced histopathology work, what proportion (by case volume) was sent to each provider as physical glass slides versus as digital whole-slide images? 8. What was the total spend on outsourced histopathology reporting in each of the two most recent completed financial years, broken down by provider? 9. Does the Trust use any insourcing arrangement (a third-party providing reporting or laboratory capacity using the Trust’s own facilities or systems)? If so, please state the provider(s), approximate volume, and spend. 10. What percentage of the Trust’s in-house histopathology reporting is currently reported digitally? Please also state the digital pathology deployment status. 11. As at 20 July 2026, and expressed in whole-time equivalents (WTE), what is the histopathology reporting workforce (including funded establishment, filled posts, vacancies, and locum or agency cover) for consultant histopathologists? 12. For any current outsourced histopathology reporting contract(s): the start and end dates, extension or renewal options, contract value, and the procurement route or framework used.

Date of Response: 21/08/2026
View Response: 11763.pdf

Freedom of Information Request Reference: 11761

Date Received: 24/07/2026

Summary:
Do you provide iron fusions for appropriate patients from other health boards in Scotland ?

Date of Response: 24/08/2026
View Response: 11761.pdf

Freedom of Information Request Reference: 11760

Date Received: 24/07/2026

Summary:
1. Total patients with hereditary angioedema (HAE, ICD-10-CM D84.1) were registered at the institution as of the end of June 2026? 2. How many patients were: a) types 1 b) type 2 c) type 3 (normal C1 inhibitor) 3. How many patients in each age range: a. 45 years 4. How many were: a) male b) female 5. Volume of medication dispensed and/or consumed from January 1st to June 30th, 2026, for each product below. If it is more convenient to specify the number of vials, pre-filled syringes, or tablets, that would also be very helpful. List of Medications: lanadelumab (Takzhyro - SC) pdC1-inhibitor (Cinryze - IV) pdC1-inhibitor (Berinert - IV and SC) rC1-inhibitor (Ruconest - IV) icatibant (Firazyr and generic - SC) berotralstat (Orladeyo cap) sebetralstat (Ekterly cap) garadacimab (Andembry - SC)

Date of Response: 18/08/2026
View Response: 11760.pdf

Freedom of Information Request Reference: 11759

Date Received: 23/07/2026

Summary:
This FOI is in relation to the Scottish Driving Assessment Service. For the 12-month period immediately preceding the date of the request, please provide: 1) The total number of driving assessments completed. 2) The number of assessments where the outcome was that the individual was assessed as: a) fit to continue driving without restriction; b) fit to continue driving subject to recommendations, restrictions or adaptations; c) not fit to continue driving (or recommended to cease driving); and d) any other outcome category used by the Service. 3) If recorded, the percentage represented by each outcome category. 4) If outcome data is recorded using different terminology, please provide the figures using the categories held by the Service together with an explanation of those categories.

Date of Response: 21/08/2026
View Response: 11759.pdf

Freedom of Information Request Reference: 11757

Date Received: 23/07/2026

Summary:
I would be grateful if you could provide the following information regarding your organisation's IT hardware estate and IT asset disposal arrangements. 1. Who is your current IT Asset Disposal (ITAD) provider? 2. When does the current ITAD contract expire? 3. What is the total annual value of the ITAD contract? 4. Was the contract awarded through a procurement framework? If so, please state which framework. 5. Approximately how many desktop PCs are currently in use? 6. Approximately how many laptops are currently in use? 7. Approximately how many tablets are currently in use? 8. Approximately how many mobile phones are currently managed? 9. Approximately how many end-user devices are disposed of each year? 10. What is your standard hardware refresh cycle for desktops and laptops? 11. Is data sanitisation performed internally or by your ITAD provider? 12. Which data erasure software or standard is used (for example, Blancco or NIST 800-88)? 13. During the last completed financial year, approximately what revenue was generated through the resale of redundant IT equipment? 14. If no revenue was generated, please confirm whether retired equipment is recycled, destroyed, or otherwise disposed of. 15. Which department is responsible for managing the ITAD contract? 16. Is your organisation expecting to procure or re-tender IT asset disposal services within the next 24 months?

Date of Response: 25/08/2026
View Response: 11757.pdf

Freedom of Information Request Reference: 11755

Date Received: 23/07/2026

Summary:
I request the following information relating to Diversity, Equity and Inclusion (DEI), Equality, Diversity and Inclusion ( EDI ), or similarly named programmes and activities within your council for the last five financial years. For each financial year, please provide: 1. DEI/ EDI Training Expenditure i.e. how much was spent on external organizations providing DEI training 2. DEI/ EDI Training Content i.e. copies of training materials, presentations, course outlines, learning objectives, handbooks, guidance documents, or other materials used for DEI/ EDI training. 3. DEI/ EDI Staff Positions i.e. list of all roles whose primary responsibility includes DEI, EDI , equality, inclusion, diversity, belonging, positive action, or related functions. Please include an annual salary or salary band.

Date of Response: 27/08/2026
View Response: 11755.pdf

Freedom of Information Request Reference: 11754

Date Received: 22/07/2026

Summary:
I am writing to request information about Mental Health services at your Trust. 1. In the last 12 months (of data), in total how many patients were managed by your Trust for the following conditions a. Schizophrenia (F20) b. Bipolar Disorder (F31) c. Other psychoses (F21-29 inclusive) 2. In the last 12 months (of data), how many patients with Schizophrenia have been treated within each of the following services: a. Early Intervention Psychosis service team b. Acute Services c. Community Mental Health Team 3. In the last 3 months (of data), how many patients with Schizophrenia were treated with each of the following antipsychotic medications a. Risperidone b. Olanzapine c. Quetiapine d. Aripiprazole e. Amisulpride f. Lurasidone g. Paliperidone h. Cariprazine i. Clozapine j. Other treatment 4. In the last 3 months (of data), how many patients with Other Psychoses were treated with each of the following antipsychotic medications a. Risperidone b. Olanzapine c. Quetiapine d. Aripiprazole e. Amisulpride f. Lurasidone g. Paliperidone h. Cariprazine i. Clozapine j. Other treatment 5. In the last 12 months (of data), how many patients with Schizophrenia were discharged to primary care from each of the following services? a. Early Intervention Psychosis service team b. Acute Services/In-patient c. Community Mental Health Team 6. In the last 12 months (of data), how many patients with Schizophrenia were discharged from the Early Intervention Psychosis service team to the Community Mental Health Team

Date of Response: 21/08/2026
View Response: 11754.pdf

Freedom of Information Request Reference: 11753

Date Received: 22/07/2026

Summary:
Q1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? 1.1 Abiraterone (Zytiga or generic abiraterone) 1.2 Apalutamide (Erleada) 1.3 Cabazitaxel 1.4 Darolutamide (Nubeqa) 1.5 Docetaxel 1.6 Enzalutamide (Xtandi) 1.7 Lutetium-177 PSMA-617 (Pluvicto) 1.7 Olaparib (Lynparza) 1.8 Relugolix (Orgovyx, Ryeqo) 1.9 Talazoparib (Talzenna) Q2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? 2.1 Docetaxel for prostate cancer 2.2 Olaparib (Lynparza) for prostate cancer 2.3 Talazoparib (Talzenna) for prostate cancer 2.4 Relugolix (Orgovyx) for prostate cancer Q3. How many patients received their first cycle or first dose of the following products in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? 3.1 Abiraterone (Zytiga or generic abiraterone) 3.2 Apalutamide (Erleada) 3.3 Cabazitaxel (Jevtana or generic cabazitaxel) 3.4 Darolutamide (Nubeqa) 3.5 Enzalutamide (Xtandi) Q4. How many patients were treated with the following combinations in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? Please give total number of patients and number of patients receiving their first dose or first cycle. 4.1 Darolutamide (Nubeqa) + Docetaxel 4.2 Darolutamide (Nubeqa) monotherapy 4.3 Olaparib (Lynparza) + Abiraterone Q5. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? 5.1 Abiraterone 5.2 Enzalutamide Q6. How many patients were treated with darolutamide (Nubeqa) for the following indications and BlueTeq CDF codes between 1st April 2026 to the end of June 2026, or latest 3-month period for which data is available? Q7. How many patients received the following products for Non-Small Cell Lung Cancer in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? 7.1 Atezolizumab (Tecentriq) 7.2 Cemiplimab (Libtayo) 7.3 Durvalumab (Imfinzi) 7.4 Nivolumab (Opdivo) 7.5 Pembrolizumab (Keytruda) Q8. How many patients received the following products for Non-Small Cell Lung Cancer as Neo-adjuvant or Adjuvant treatment in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? 8.1 Atezolizumab 8.2 Durvalumab 8.3 Nivolumab 8.4 Pembrolizumab 8.5 Durvalumab Q9. How many patients received the following combination or monotherapy for Non-Small Cell Lung Cancer in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? 9.1 Cemiplimab + Cisplatin or Carboplatin chemotherapy 9.2 Cemiplimab monotherapy

Date of Response: 21/08/2026
View Response: 11753.pdf

Freedom of Information Request Reference: 11751

Date Received: 21/07/2026

Summary:
The response provided is factually irreconcilable with a previous executive-signed disclosure issued by the Board. This creates a data integrity failure that undermines the public’s confidence in the Board’s governance. Direct Contradiction: In a response dated 16/06/2026 (Ref: 11597), signed by the Executive Director of Nursing, the Board explicitly confirmed: "Yes [we utilize stapler devices]" and provided specific technical data (e.g., "Dual grip", "15 minutes" for stapler procedures). In the response under review, the Board stated: "Staplers are not used in NHS Lothian’s theatres." Governance Failure: These statements are mutually exclusive. It is not possible for both disclosures to be accurate. As both documents bear the signature of the same Executive Director, this suggests a systemic failure in the Board’s ability to verify the accuracy of clinical information before it is formally released to the public. Requested Resolution: Under the Freedom of Information (Scotland) Act 2002, I request that a senior officer not involved in the original decision conducts an investigation to: Identify which of the two contradictory statements is factually correct. Detail the "mechanism of failure" that allowed the Board to issue two completely different accounts of its own surgical capabilities within a 30-day period. Confirm if the inaccurate disclosure has been reported to the Board’s Information Governance lead for correction. Provide a formal, corrected statement regarding the Board's current policy and usage of stapler-assisted surgical technology.

Date of Response: 25/08/2026
View Response: 11751.pdf

Freedom of Information Request Reference: 11750

Date Received: 14/07/2026

Summary:
1. What’s CMT? 2. The August 2022 note says that the next review was to be on March 31 2023. Can you send me a copy of that (and any more recent reviews)? 3. Has this decision never been discussed or approved by Lothian Health Board? 4. Also, the July 5th minute says this: "three orthodontic consultants (2.2wte out of 3.2wte) have made decisions to either retire or move to other roles / areas, and thus there is an emergent pressure within orthodontics as recruitment continues.” After almost four years, what has been the result of that recruitment?

Date of Response: 28/07/2026
View Response: 11750.pdf

Freedom of Information Request Reference: 11746

Date Received: 20/07/2026

Summary:
Please can you assist with supplying the answers to the below questions: • Number of shifts booked by ON Framework agency staff broken down by provider and month from 1st March 2026 To 30th June 2026 • Number of shifts booked by OFF Framework agency staff broken down by provider and month from 1st March 2026 To 30th June 2026 • Total spend on ON Framework agency staff broken down by agency and month from 1st March 2026 To 30th June 2026 • Total spend on OFF Framework agency staff broken down by agency and month from 1st March 2026 to 30th June 2026 • Where has the health board been utilising the support for agency staffing support the most from 1st March to 30th June 2026, is it in your hospitals, community care or residential care? • Can you provide a total sum of agency expenditure across all areas of healthcare from the 1st of March 2026 - 30th June 2026?

Date of Response: 28/08/2026
View Response: 11746.pdf